This study evaluated the effects of MCC950, a selective inhibitor of the NLRP3 inflammasome, on metabolic and autonomic parameters in an experimental model of type 1 diabetes mellitus (T1DM). The investigators aimed to determine whether pharmacologic NLRP3 inhibition could improve glycemic control, lipid abnormalities, and markers of sympathetic dysfunction associated with STZ-induced T1DM in rats.
Male Wistar rats were rendered diabetic by a single intraperitoneal injection of streptozotocin (STZ) at 50 mg/kg. Successful induction of T1DM was confirmed by persistent hyperglycemia, decreased serum C-peptide concentrations, and characteristic pancreatic histopathological changes consistent with beta-cell injury. Prior to initiating treatment, diabetic animals also demonstrated elevated serum noradrenaline (NA), used in this study as a biochemical indicator of sympathetic overactivity and as evidence of diabetic cardiac autonomic neuropathy.
After confirmation of diabetes and autonomic disturbance, diabetic rats were assigned to receive one of three interventions for a four-week treatment period: MCC950, insulin, or normal saline (untreated control). The report describes outcome measures collected both before and after the four-week treatment interval.
The primary metabolic and autonomic endpoints measured were fasting blood glucose, serum lipid profile (total cholesterol, triglycerides, LDL-cholesterol, and HDL-cholesterol), serum C-peptide, pancreatic histology, and serum noradrenaline. These assessments were performed at baseline (pre-treatment) and following the four-week treatment course to evaluate changes attributable to MCC950 or comparators.
Rats treated with MCC950 showed statistically significant reductions in fasting blood glucose compared with untreated diabetic controls. In parallel, MCC950 treatment markedly lowered serum total cholesterol, triglyceride, and LDL‑cholesterol concentrations (all reported as P<0.0001 versus untreated diabetic rats). HDL‑cholesterol did not change with MCC950 treatment. These findings indicate an overall improvement in diabetes-associated dyslipidemia with NLRP3 inhibition in this model.
MCC950-treated animals exhibited a partial restoration of serum C-peptide levels compared with untreated diabetic rats. The treatment was also associated with improvements in pancreatic histopathology, consistent with some preservation or recovery of pancreatic structure relative to untreated animals. The report presents these effects as evidence that MCC950 influenced pancreatic beta-cell–related biomarkers and tissue appearance, though the degree of restoration was described as partial rather than complete.
Elevated serum noradrenaline (NA) prior to therapy served as an indicator of sympathetic overactivity in the diabetic cohort. Following MCC950 administration, serum NA concentrations were reduced relative to untreated diabetic animals, suggesting an attenuation of biochemical markers of sympathetic activation. The authors emphasize, however, that direct functional measures of cardiac autonomic function were not performed in this study.
The aggregate results support the concept that pharmacologic inhibition of the NLRP3 inflammasome with MCC950 can favorably modulate both metabolic abnormalities (hyperglycemia and dyslipidemia) and biomarkers of sympathetic dysfunction in an STZ-induced T1DM rat model. Partial recovery of C-peptide and improved pancreatic histology point to effects on pancreatic function or preservation. Reduced serum NA suggests a downstream influence on sympathetic tone or stress signaling.
Key limitations reported by the authors include the absence of direct functional assessments of cardiac autonomic function; serum noradrenaline was used as a biochemical marker but does not substitute for electrophysiological or reflex testing. The design and outcomes are preclinical and limited to a single animal model (male Wistar rats with STZ 50 mg/kg). The authors recommend further studies that incorporate direct functional measures of autonomic performance to more clearly define the role of NLRP3 inhibition in diabetic cardiac autonomic neuropathy and to validate translational potential.
In this STZ-induced T1DM rat model, MCC950 treatment over four weeks was associated with lower fasting blood glucose, reduced total cholesterol, triglycerides, and LDL‑cholesterol (all P<0.0001 versus untreated diabetics), unchanged HDL, partial restoration of C-peptide, improved pancreatic histology, and decreased serum noradrenaline. These findings suggest that NLRP3 inflammasome inhibition may ameliorate several metabolic disturbances and biochemical markers of sympathetic overactivity in experimental T1DM. Additional preclinical work including direct autonomic function testing is required before considering translational steps.